Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
Browsing: Parasitic > Malaria
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
With progress plateauing for a second consecutive year and global financing also levelling off, the WHO has called for a ‘high burden to high impact’ country-led strategy.
Researchers from Imperial College London have reported their recent success in using ‘gene drive’ technology to block female mosquito reproduction, resulting in the total collapse of caged populations of Anopheles gambiae in as little as 7–11 generations.
A team of researchers from Imperial College London (UK) have identified compounds which prevent the malarial parasite sexually maturing inside the mosquito.
Genomics is increasingly being adopted into both research and clinical settings. Here, we speak to Dyann Wirth about the use of genomics in the field of malaria, from what it can uncover about the parasite to the hurdles that need to be overcome moving towards elimination.
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.